contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-conference-call-regarding-promore-pharmas-interim-report-for-the-second-quarter-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Promore Pharma

STOCKHOLM, 23 August 2022 – Promore Pharma AB (publ) publishes its interim report for the second quarter 2022 on 30 August 2022.The same day the company will host a webcast telephone conference...

<div class="mfn-preamble"><p><strong>STOCKHOLM, 23 August 2022 – Promore Pharma AB (publ) publishes its interim report for the second quarter 2022 on 30 August 2022.</strong></p></div><div class="mfn-body"><p>The same day the company will host a webcast telephone conference at 13.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&amp;A session. The conference call will be held in Swedish and can be accessed via computer, tablet, or telephone.</p><p>The number of attendees is limited, please register for the conference in advance on the following link:</p><p><a rel="nofollow noopener" href="https://attendee.gotowebinar.com/register/983107856267119885">https://attendee.gotowebinar.com/register/983107856267119885</a></p><p>The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.</p></div><div class="mfn-footer mfn-contacts mfn-c00f131ce405"><p><strong class="mfn-heading-1">For additional information, please contact</strong></p><hr><p>Jonas Ekblom, CEO<br>Phone: [+46] 736 777&nbsp;540<br>E-mail: <a rel="nofollow noopener" href="mailto:jonas.ekblom@promorepharma.com">jonas.ekblom@promorepharma.com</a></p><p>Erik Magnusson, CFO<br>Phone: [+46] 708 565 245<br>E-mail: <a rel="nofollow noopener" href="mailto:erik.magnusson@promorepharma.com">erik.magnusson@promorepharma.com</a><br><strong><br></strong>Promore Pharmas Certified Adviser is Erik Penser Bank<br>Tel: [+46] 8-463 83 00<br>E-mail: <a rel="nofollow noopener" href="mailto:certifiedadviser@penser.se">certifiedadviser@penser.se</a></p></div><div class="mfn-footer mfn-about mfn-4877aba8bb36"><p><strong class="mfn-heading-1">Promore Pharma in brief</strong></p><hr><p>Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is undergoing a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/7d1c9dc9-d243-4acb-9373-7b5a9e7cbc52/invitation-to-conference-call-regarding-promore-pharmas-interim-report-for-the-second-quarter-2022.pdf" class="mfn-generated mfn-primary">Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022</a></p></div>

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022